Trileptal, Oxcarbazepine Newswire

Trileptal, Oxcarbazepine Newswire

Comprehensive Real-Time News Feed for Trileptal, Oxcarbazepine (generic).

Results 1 - 20 of 430 in Trileptal, Oxcarbazepine (generic)

  1. Supernus Pharmaceuticals Inc (SUPN) Given Consensus Recommendation of "Buy" by AnalystsRead the original story w/Photo

    19 hrs ago | AmericanBankingNews.com

    Supernus Pharmaceuticals Inc has earned an average rating of "Buy" from the six brokerages that are currently covering the stock. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating on the company.

    Comment?

  2. Analysts' Recent Ratings Changes for Supernus PharmaceuticalsRead the original story w/Photo

    Tuesday | AmericanBankingNews.com

    They now have a "buy" rating on the stock. 3/7/2017 - Supernus Pharmaceuticals had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.

    Comment?

  3. Supernus: Label Expansion, Trokendi Settlement Catalysts For More UpsideRead the original story w/Photo

    Thursday Mar 16 | Seeking Alpha

    Supernus reported another very solid quarter with robust sales and operating income growth. The company guided for 2017 sales in the $265-275 million range, which is right in line with my estimate range for the year.

    Comment?

  4. Oxcarbazepine Tablets Market Trends & Forecast to 2021- Industry...Read the original story

    Sunday Mar 12 | Emailwire.com

    Global Oxcarbazepine Tablets market research report is a professional and in-depth study on the current state of the Oxcarbazepine Tablets. Various definitions and classification of the industry, applications of the industry and chain structure are given Global Oxcarbazepine Tablets market research report is a professional and in-depth study on the current state of the Oxcarbazepine Tablets.

    Comment?

  5. Oxcarbazepine (API) Market Size, Share, Growth, Trends, Demand and Forecast to 2021Read the original story

    Sunday Mar 12 | Emailwire.com

    Global Oxcarbazepine market research report is a professional and in-depth study on the current state of the Oxcarbazepine . Various definitions and classification of the industry, applications of the industry and chain structure are given Global Oxcarbazepine market research report is a professional and in-depth study on the current state of the Oxcarbazepine .

    Comment?

  6. Oxcarbazepine Market Trends & Forecast to 2021- Industry Analysis by Regions, Type and ApplicationRead the original story

    Sunday Mar 12 | Emailwire.com

    Global Oxcarbazepine market research report is a professional and in-depth study on the current state of the Oxcarbazepine. Various definitions and classification of the industry, applications of the industry and chain structure are given.

    Comment?

  7. Supernus Pharmaceuticals Inc (SUPN) Given "Overweight" Rating at Cantor FitzgeraldRead the original story w/Photo

    Sunday Mar 12 | AmericanBankingNews.com

    's stock had its "overweight" rating reaffirmed by equities researchers at Cantor Fitzgerald in a research report issued to clients and investors on Tuesday. They currently have a $31.00 price target on the specialty pharmaceutical company's stock.

    Comment?

  8. Supernus Pharmaceuticals Inc (SUPN) Forecasted to Earn FY2020 Earnings of $3.00 Per ShareRead the original story w/Photo

    Sunday Mar 12 | IntersportsWire

    Supernus Pharmaceuticals Inc - Investment analysts at Jefferies Group dropped their FY2020 earnings per share estimates for Supernus Pharmaceuticals in a report issued on Tuesday. Jefferies Group analyst D. Steinberg now anticipates that the brokerage will post earnings of $3.00 per share for the year, down from their prior estimate of $3.09.

    Comment?

  9. Jefferies Group Analysts Reduce Earnings Estimates for Supernus Pharmaceuticals IncRead the original story w/Photo

    Saturday Mar 11 | The Breeze

    Supernus Pharmaceuticals Inc - Research analysts at Jefferies Group decreased their FY2021 EPS estimates for Supernus Pharmaceuticals in a research report issued on Tuesday. Jefferies Group analyst D. Steinberg now expects that the firm will earn $4.36 per share for the year, down from their previous estimate of $4.51.

    Comment?

  10. Cantor Fitzgerald Weighs in on Supernus Pharmaceuticals Inc's FY2017 EarningsRead the original story w/Photo

    Saturday Mar 11 | IntersportsWire

    Supernus Pharmaceuticals Inc - Analysts at Cantor Fitzgerald issued their FY2017 earnings estimates for shares of Supernus Pharmaceuticals in a report issued on Monday. Cantor Fitzgerald analyst W. Tanner expects that the brokerage will earn $1.38 per share for the year.

    Comment?

  11. Jefferies Group Analysts Cut Earnings Estimates for Supernus Pharmaceuticals IncRead the original story w/Photo

    Friday Mar 10 | AmericanBankingNews.com

    Supernus Pharmaceuticals Inc - Stock analysts at Jefferies Group decreased their FY2020 earnings estimates for Supernus Pharmaceuticals in a research report issued to clients and investors on Tuesday. Jefferies Group analyst D. Steinberg now anticipates that the firm will post earnings per share of $3.00 for the year, down from their previous estimate of $3.09.

    Comment?

  12. Supernus Pharmaceuticals Inc (SUPN) Forecasted to Post FY2018 Earnings of $1.91 Per ShareRead the original story w/Photo

    Friday Mar 10 | IntersportsWire

    Supernus Pharmaceuticals Inc - Analysts at SunTrust Banks decreased their FY2018 earnings per share estimates for shares of Supernus Pharmaceuticals in a report issued on Monday. SunTrust Banks analyst J. Boris now anticipates that the firm will earn $1.91 per share for the year, down from their previous estimate of $2.00.

    Comment?

  13. Supernus Pharmaceuticals Inc (SUPN) PT Raised to $35.00Read the original story w/Photo

    Friday Mar 10 | IntersportsWire

    The brokerage currently has a "buy" rating on the specialty pharmaceutical company's stock. Jefferies Group LLC's price objective indicates a potential upside of 27.97% from the company's previous close.

    Comment?

  14. Supernus Pharmaceuticals Inc (SUPN) Shares Up 5.3% Following Analyst UpgradeRead the original story w/Photo

    Friday Mar 10 | IntersportsWire

    Supernus Pharmaceuticals Inc 's share price shot up 5.3% during trading on Wednesday after Jefferies Group raised their price target on the stock from $33.00 to $35.00. Jefferies Group currently has a buy rating on the stock.

    Comment?

  15. Supernus Pharmaceuticals Inc Expected to Earn FY2017 Earnings of $1.38 Per ShareRead the original story w/Photo

    Thursday Mar 9 | Daily Political

    Supernus Pharmaceuticals Inc - Cantor Fitzgerald issued their FY2017 earnings estimates for shares of Supernus Pharmaceuticals in a report issued on Monday. Cantor Fitzgerald analyst W. Tanner expects that the firm will post earnings per share of $1.38 for the year.

    Comment?

  16. Supernus Pharmaceuticals Inc (SUPN) Rating Reiterated by Cantor FitzgeraldRead the original story w/Photo

    Thursday Mar 9 | Daily Political

    's stock had its "overweight" rating reaffirmed by research analysts at Cantor Fitzgerald in a research note issued on Tuesday. They presently have a $31.00 price objective on the specialty pharmaceutical company's stock.

    Comment?

  17. Supernus Pharmaceuticals (SUPN) - Research Analysts' Recent Ratings ChangesRead the original story w/Photo

    Wednesday Mar 8 | AmericanBankingNews.com

    They now have a "buy" rating on the stock. 3/7/2017 - Supernus Pharmaceuticals had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.

    Comment?

  18. Supernus Pharmaceuticals Inc (SUPN) PT Raised to $35.00 at Jefferies Group LLCRead the original story w/Photo

    Wednesday Mar 8 | AmericanBankingNews.com

    The brokerage presently has a "buy" rating on the specialty pharmaceutical company's stock. Jefferies Group LLC's target price points to a potential upside of 25.90% from the company's previous close.

    Comment?

  19. Supernus Pharmaceuticals Inc (SUPN) Price Target Raised to $35.00 at Jefferies Group LLCRead the original story w/Photo

    Wednesday Mar 8 | Daily Political

    Jefferies Group LLC's target price would suggest a potential upside of 32.58% from the company's previous close. A number of other research analysts have also recently commented on SUPN.

    Comment?

  20. Revenue Update on Supernus Pharmaceuticals IncRead the original story

    Tuesday Mar 7 | The Oak Ridge Observer

    Supernus Pharmaceuticals, Inc. , a Healthcare sector firm, traded 899879 shares in last trading session with closing price of $29.75 per share. The Company markets its products in the United States through its own specialty sales force and has collaborations with other pharmaceutical companies to license its products outside the United States.

    Comment?